EyePoint Pharmaceuticals Statistics
Share Statistics
EyePoint Pharmaceuticals has 68.81M
shares outstanding. The number of shares has increased by 31.96%
in one year.
| Shares Outstanding | 68.81M |
| Shares Change (YoY) | 31.96% |
| Shares Change (QoQ) | 0.7% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,003 |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 10.07M, so 14.64% of the outstanding
shares have been sold short.
| Short Interest | 10.07M |
| Short % of Shares Out | 14.64% |
| Short % of Float | 17.55% |
| Short Ratio (days to cover) | 15.58 |
Valuation Ratios
The PE ratio is -3.2 and the forward
PE ratio is -1.99.
EyePoint Pharmaceuticals's PEG ratio is
-0.12.
| PE Ratio | -3.2 |
| Forward PE | -1.99 |
| PS Ratio | 9.69 |
| Forward PS | 0.6 |
| PB Ratio | 1.25 |
| P/FCF Ratio | -3.22 |
| PEG Ratio | -0.12 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for EyePoint Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.81,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.81 |
| Quick Ratio | 7.77 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.17 |
| Interest Coverage | -10418.14 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $262,260.61 |
| Profits Per Employee | $-793,151.52 |
| Employee Count | 165 |
| Asset Turnover | 0.1 |
| Inventory Turnover | 1.61 |
Taxes
| Income Tax | 90K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by -54.39% in the
last 52 weeks. The beta is 1.6, so EyePoint Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.6 |
| 52-Week Price Change | -54.39% |
| 50-Day Moving Average | 6.06 |
| 200-Day Moving Average | 7.9 |
| Relative Strength Index (RSI) | 44.3 |
| Average Volume (20 Days) | 788,808 |
Income Statement
In the last 12 months, EyePoint Pharmaceuticals had revenue of 43.27M
and earned -130.87M
in profits. Earnings per share was -2.32.
| Revenue | 43.27M |
| Gross Profit | 39.56M |
| Operating Income | -145.85M |
| Net Income | -130.87M |
| EBITDA | -129.23M |
| EBIT | -130.77M |
| Earnings Per Share (EPS) | -2.32 |
Full Income StatementBalance Sheet
The company has 99.7M in cash and 21.86M in
debt, giving a net cash position of 77.85M.
| Cash & Cash Equivalents | 99.7M |
| Total Debt | 21.86M |
| Net Cash | 77.85M |
| Retained Earnings | -873.02M |
| Total Assets | 418.46M |
| Working Capital | 334.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -126.23M
and capital expenditures -4.05M, giving a free cash flow of -130.28M.
| Operating Cash Flow | -126.23M |
| Capital Expenditures | -4.05M |
| Free Cash Flow | -130.28M |
| FCF Per Share | -2.31 |
Full Cash Flow StatementMargins
Gross margin is 91.42%, with operating and profit margins of -337.06% and -302.43%.
| Gross Margin | 91.42% |
| Operating Margin | -337.06% |
| Pretax Margin | -302.22% |
| Profit Margin | -302.43% |
| EBITDA Margin | -298.63% |
| EBIT Margin | -337.06% |
| FCF Margin | -301.06% |
